The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations

Trevor J. Mathias(University of Maryland, Baltimore), Maria R. Baer(University of Maryland, Baltimore), Karthika Natarajan(Center for Drug Evaluation and Research), Zeba N. Singh(University of Maryland, Baltimore), Suneet Shukla(National Cancer Institute), Kshama A. Doshi(U-M Rogel Cancer Center), Suresh V. Ambudkar(National Institutes of Health)
Investigational New Drugs
January 19, 2015
10.1007/s10637-015-0205-y
Cited by 28

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
|Journal of Clinical Oncology|2012|408